Online Drug Sellers Lead China Tech Losses on Fears of Sales Ban

Weakness in pharmaceutical shares and concerns of a global recession led the Hang Seng Tech Index to a decline of 4.4%.

(Bloomberg) — Shares of China’s online drug sellers slumped in Hong Kong Wednesday after a media report renewed concerns that Beijing may ban third-party platforms from offering medicines over the internet.

Alibaba Health Information Technology Ltd. plunged 14%, and JD Health International Inc. tumbled 15%, wiping out three days of strong gains. Weakness in pharmaceutical shares and concerns of a global recession led the Hang Seng Tech Index to a decline of 4.4%.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Dine-in Services Resume in Shanghai

PODCAST

Caixin China Biz Roundup: China Cuts Quarantine Stays for Inbound Travelers

MOST POPULAR

1: Cover Story: How Bad Is China’s Manufacturing Exodus?

2: After Junk Downgrade, China’s Largest Developer Announces $441 Million Bond Buyback

3: CATL Unveils Battery That Power a Car Up to 1,000 Kilometers on One Charge

4: Roundup: Where Analysts Think China’s Economy Is Going This Year

5: Two Killed in Nio Test Car That Fell From Third Floor